Aclaris Therapeutics Inc (NASDAQ:ACRS) – Stock analysts at William Blair issued their Q1 2018 earnings estimates for shares of Aclaris Therapeutics in a research note issued to investors on Monday. William Blair analyst T. Lugo expects that the biotechnology company will earn ($0.97) per share for the quarter. William Blair also issued estimates for Aclaris Therapeutics’ Q2 2018 earnings at ($0.96) EPS, Q3 2018 earnings at ($0.96) EPS and Q4 2018 earnings at ($0.96) EPS.
Several other equities research analysts have also commented on ACRS. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Monday. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 19th. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 price target for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $41.80.
Several hedge funds have recently bought and sold shares of ACRS. Northern Trust Corp grew its stake in shares of Aclaris Therapeutics by 51.8% in the second quarter. Northern Trust Corp now owns 255,738 shares of the biotechnology company’s stock valued at $6,936,000 after buying an additional 87,250 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Aclaris Therapeutics by 14.2% in the second quarter. Vanguard Group Inc. now owns 812,318 shares of the biotechnology company’s stock valued at $22,029,000 after buying an additional 100,799 shares in the last quarter. Voya Investment Management LLC acquired a new stake in shares of Aclaris Therapeutics in the second quarter valued at about $247,000. State Street Corp grew its stake in shares of Aclaris Therapeutics by 67.1% in the second quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock valued at $8,971,000 after buying an additional 132,866 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Aclaris Therapeutics by 69.7% in the second quarter. The Manufacturers Life Insurance Company now owns 15,831 shares of the biotechnology company’s stock valued at $429,000 after buying an additional 6,502 shares in the last quarter. Institutional investors and hedge funds own 92.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/equities-analysts-issue-forecasts-for-aclaris-therapeutics-incs-q1-2018-earnings-acrs.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.